Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 5:01 Acquisition Corp.FVAM · Entity 144989 | Director | October 16, 2020 | October 21, 2020 |
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP & Global Head of R&D | February 27, 2017 | March 01, 2017 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | May 08, 2026 | May 11, 2026 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PFIZER INCPFE · Entity 2863 | Senior Vice President | May 14, 2010 | May 18, 2010 |
| Rallybio CorpRLYB · Entity 6838 | Director | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
5:01 Acquisition Corp.
Report date October 16, 2020 · Filed October 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2020-10-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-16 · Other · Acquired 30,000 · Balance 30,000 F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors. F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are automatically convertible into the issuer's shares of Class A common stock at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment pursuant to certain anti-dilution rights, and have no expiration date. The shares of Class B common stock are subject to forfeiture under certain circumstances relating to the Reporting Person's service on the issuer's Board of Directors.
F2: In connection with the issuer's initial public offering and the Reporting Person's appointment to the issuer's Board of Directors, 5:01 Acquisition LLC transferred 30,000 shares of Class B common stock to the Reporting Person.
ALEXION PHARMACEUTICALS, INC.
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 50,688 |
Ending reported balance
After 2017-03-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2017-02-27 · Sale · Disposed 860 · Balance 38,883 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 2 · 2017-02-28 · Sale · Disposed 625 · Balance 38,258 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 3 · 2017-02-28 · Grant · Acquired 12,800 · Balance 51,058 F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Row 4 · 2017-03-01 · Sale · Disposed 370 · Balance 50,688 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $131.25 · Expires 2027-02-28 | Direct | 12,800 |
Reported balance
After 2017-02-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-02-28 · Grant · Acquired 12,800 · Balance 12,800 F5: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
F2: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F5: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,137 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 1,438 · Balance 15,730 F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders. Row 2 · 2026-05-08 · Grant · Acquired 1,407 · Balance 17,137 F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PFIZER INC
Report date May 14, 2010 · Filed May 18, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 10,637 |
Reported balance
After 2010-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-05-14 · Grant · Acquired 236 · Balance 10,637 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Rallybio Corp
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 · Expires 2036-02-18 | Direct | 18,055 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 18,055 · Balance 18,055 F1: The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026. F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to the underlying shares of Common Stock in 11 equal installments, each on the last day of each remaining month of calendar year 2026.
F2: This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $65,000.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SpringWorks Therapeutics, Inc.
Report date July 01, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 1
1 source rowRow 1 · 2025-07-01 · Disposition to issuer · Disposed 20,023 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Represents shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock. F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.80 | Direct | 0 |
Reported balance
After 2025-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-01 · Disposition to issuer · Disposed 29,445 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6) F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the "Merger Agreement"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners ("Parent"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Represents shares underlying restricted stock units (each, an "RSU") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Issuer common stock.
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the "Merger Consideration").
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a "Parent Cash-Based RSU Award"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 6)
F6: (Continued from footnote 5) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a "Parent Cash-Based Option Award"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2017 Filed Aug 3, 2017 12:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-024821 · form4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,175 F1 · kind: Consists of 2,175 unvested restricted stock units that vest on 8/1/2018. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 370 | $132.50 | $49,025.00 |
DisclosureSEC source: 0000899866-17-000057 · wf-form4_148841551440469.xml · nonDerivative · entry 4 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,688 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantOption to Purchase Common Stock · Derivative | 12,800 | $0.00 Strike: $131.25 | $0.00 |
DisclosureSEC source: 0000899866-17-000057 · wf-form4_148841551440469.xml · derivative · entry 5 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock, par value $.0001 per share · 12,800 shares Expires 2027-02-28 F5 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000057 · wf-form4_148841551440469.xml · nonDerivative · entry 3 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,058 F3 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 625 | $131.70 | $82,312.50 |
DisclosureSEC source: 0000899866-17-000057 · wf-form4_148841551440469.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,258 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 19:45 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 860 | $131.20 | $112,832.00 |
DisclosureSEC source: 0000899866-17-000057 · wf-form4_148841551440469.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,883 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 09, 2017 Filed Feb 10, 2017 18:05 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 217 | $126.84 | $27,524.28 |
DisclosureSEC source: 0000899866-17-000037 · wf-form4_148676790634604.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,743 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 18 | $126.88 | $2,283.84 |
DisclosureSEC source: 0000899866-17-000025 · wf-form4_148658993769140.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,960 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 16:39 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock, par value $.0001 per share | 2,710 | $125.69 | $340,619.90 |
DisclosureSEC source: 0000899866-17-000025 · wf-form4_148658993769140.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · EVP & Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,978 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| May 14, 2010 Filed May 18, 2010 19:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 236 | $16.20 | $3,823.20 |
DisclosureSEC source: 0001225208-10-013292 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,637 Underlying: Common Stock · 236 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2010 Filed May 3, 2010 19:43 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 117 | $16.72 | $1,956.24 |
DisclosureSEC source: 0001225208-10-011619 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,401 Underlying: Common Stock · 117 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2010 Filed Apr 16, 2010 21:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 115 | $16.99 | $1,953.85 |
DisclosureSEC source: 0001225208-10-010496 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,284 Underlying: Common Stock · 115 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2010 Filed Apr 1, 2010 22:40 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 111 | $17.15 | $1,903.65 |
DisclosureSEC source: 0001225208-10-009468 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,169 Underlying: Common Stock · 111 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 15, 2010 Filed Mar 17, 2010 13:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 2,718 | $17.26 | $46,912.68 |
DisclosureSEC source: 0001225208-10-008383 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,058 Underlying: Common Stock · 2,718 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 163,288 | $0.00 Strike: $17.69 | $0.00 |
DisclosureSEC source: 0001225208-10-006399 · doc4.xml · derivative · entry 5 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,288 Underlying: Common Stock · 163,288 shares Expires 2015-02-25 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 1,127 | $17.69 | $19,936.63 |
DisclosureSEC source: 0001225208-10-006399 · doc4.xml · nonDerivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,044 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance-Contingent Shares. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 3,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-006399 · doc4.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 376,171 F2 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares. Read SEC document |
| February 25, 2010 Filed Mar 2, 2010 02:01 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 66,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-10-006399 · doc4.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,700 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| December 31, 2009 Filed Jan 4, 2010 21:12 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 104 | $18.19 Strike: $0.00 | $1,891.76 |
DisclosureSEC source: 0001225208-10-000246 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,265 Underlying: Common Stock · 104 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2009 Filed Dec 16, 2009 22:08 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 103 | $18.29 Strike: $0.00 | $1,883.87 |
DisclosureSEC source: 0001225208-09-024591 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,161 Underlying: Common Stock · 103 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 30, 2009 Filed Dec 1, 2009 21:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 102 | $18.17 Strike: $0.00 | $1,853.34 |
DisclosureSEC source: 0001225208-09-023535 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,058 Underlying: Common Stock · 102 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 13, 2009 Filed Nov 17, 2009 00:35 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 169 | $17.59 Strike: $0.00 | $2,972.71 |
DisclosureSEC source: 0001225208-09-022353 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,956 Underlying: Common Stock · 169 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 30, 2009 Filed Nov 3, 2009 21:37 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 112 | $17.03 Strike: $0.00 | $1,907.36 |
DisclosureSEC source: 0001225208-09-021512 · doc4.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,787 Underlying: Common Stock · 112 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2009 Filed Oct 16, 2009 20:45 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 106 | $17.66 | $1,871.96 |
DisclosureSEC source: 0000078003-09-000222 · primary_doc.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,675 Underlying: Common Stock · 106 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 30, 2009 Filed Oct 1, 2009 17:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 115 | $16.55 | $1,903.25 |
DisclosureSEC source: 0000078003-09-000209 · primary_doc.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,569 Underlying: Common Stock · 115 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 15, 2009 Filed Sep 16, 2009 23:23 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 119 | $16.21 | $1,928.99 |
DisclosureSEC source: 0000078003-09-000194 · primary_doc.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,454 Underlying: Common Stock · 119 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2009 Filed Sep 1, 2009 21:30 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 109 | $16.70 | $1,820.30 |
DisclosureSEC source: 0000078003-09-000184 · primary_doc.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,335 Underlying: Common Stock · 109 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 14, 2009 Filed Aug 18, 2009 15:31 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 182 | $15.77 | $2,870.14 |
DisclosureSEC source: 0000078003-09-000174 · mac2117.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,226 Underlying: Common Stock · 182 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2009 Filed Aug 4, 2009 15:10 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 119 | $15.93 | $1,895.67 |
DisclosureSEC source: 0000078003-09-000166 · mac2108.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,044 Underlying: Common Stock · 119 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 15, 2009 Filed Jul 16, 2009 19:56 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 126 | $15.02 | $1,892.52 |
DisclosureSEC source: 0000078003-09-000154 · mac2100.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,925 Underlying: Common Stock · 126 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 30, 2009 Filed Jul 1, 2009 20:24 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 124 | $15.00 | $1,860.00 |
DisclosureSEC source: 0000078003-09-000139 · mac2082.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,799 Underlying: Common Stock · 124 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| June 15, 2009 Filed Jun 16, 2009 19:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 136 | $14.13 | $1,921.68 |
DisclosureSEC source: 0000078003-09-000127 · mac2066.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,675 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 29, 2009 Filed Jun 2, 2009 13:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 125 | $15.19 | $1,898.75 |
DisclosureSEC source: 0000078003-09-000116 · mac2052.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,539 Underlying: Common Stock · 125 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| May 15, 2009 Filed May 18, 2009 20:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 180 | $15.01 | $2,701.80 |
DisclosureSEC source: 0000078003-09-000106 · mac2041.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,414 Underlying: Common Stock · 180 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 30, 2009 Filed May 1, 2009 18:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 141 | $13.36 | $1,883.76 |
DisclosureSEC source: 0000078003-09-000096 · mac2031.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,234 Underlying: Common Stock · 141 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| April 15, 2009 Filed Apr 16, 2009 21:20 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 138 | $13.86 | $1,912.68 |
DisclosureSEC source: 0000078003-09-000073 · mac2009.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,093 Underlying: Common Stock · 138 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 31, 2009 Filed Apr 1, 2009 20:06 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 148 | $13.62 | $2,015.76 |
DisclosureSEC source: 0000078003-09-000060 · mac1999.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,955 Underlying: Common Stock · 148 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| March 13, 2009 Filed Mar 16, 2009 20:50 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 2,889 | $14.54 | $42,006.06 |
DisclosureSEC source: 0000078003-09-000047 · mac1985.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,807 Underlying: Common Stock · 2,889 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:27 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 83,955 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000078003-09-000033 · mac1968.xml · derivative · entry 6 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,955 Underlying: Common Stock · 83,955 shares Expires 2014-02-26 F5 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F5 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:27 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 4,234 | $12.70 | $53,771.80 |
DisclosureSEC source: 0000078003-09-000033 · mac1968.xml · derivative · entry 5 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,234 Underlying: Common Stock · 4,234 shares Expires not disclosed F3 · derivative.exercise_price: Each unit represents one phantom share of common stock. F4 · derivative.exercise_date: Units represent incentive compensation that has been deferred. Units will be settled in cash following separation from service. F4 · derivative.expiration_date: Units represent incentive compensation that has been deferred. Units will be settled in cash following separation from service. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:27 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 5,837 | $12.70 | $74,129.90 |
DisclosureSEC source: 0000078003-09-000033 · mac1968.xml · nonDerivative · entry 3 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,581 Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:27 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 37,114 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000033 · mac1968.xml · nonDerivative · entry 2 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,418 F2 · shares: The reported transaction constitutes the earn-out of Performance-Contingent Shares and Performance Shares. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:27 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 99,868 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-09-000033 · mac1968.xml · nonDerivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,304 F1 · shares: The reported transaction constitutes the grant of restricted stock units. Read SEC document |
| February 26, 2009 Filed Mar 3, 2009 22:00 UTC Amendment | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 195,896 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0000078003-09-000041 · mac1978.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,896 Underlying: Common Stock · 195,896 shares Expires 2014-02-26 F1 · shares: Amendment filed to correct the number of stock appreciation rights granted on February 26, 2009. F2 · derivative.exercise_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant F2 · derivative.expiration_date: The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant Read SEC document |
| December 31, 2008 Filed Jan 5, 2009 12:58 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 95 | $17.71 | $1,682.45 |
DisclosureSEC source: 0000078003-09-000007 · mac1948.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 Underlying: Common Stock · 95 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 15, 2008 Filed Dec 16, 2008 23:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 101 | $16.63 | $1,679.63 |
DisclosureSEC source: 0000078003-08-000314 · mac1937.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,775 Underlying: Common Stock · 101 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 26, 2008 Filed Dec 1, 2008 22:25 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 105 | $16.07 | $1,687.35 |
DisclosureSEC source: 0000078003-08-000303 · mac1926.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,674 Underlying: Common Stock · 105 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| November 14, 2008 Filed Nov 17, 2008 21:44 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 131 | $16.28 | $2,132.68 |
DisclosureSEC source: 0000078003-08-000292 · mac1915.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,569 Underlying: Common Stock · 131 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 31, 2008 Filed Nov 3, 2008 19:53 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 95 | $17.71 | $1,682.45 |
DisclosureSEC source: 0000078003-08-000274 · mac1904.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,438 Underlying: Common Stock · 95 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| October 15, 2008 Filed Oct 16, 2008 18:51 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units SSP · Derivative | 104 | $16.27 | $1,692.08 |
DisclosureSEC source: 0000078003-08-000266 · mac1892.xml · derivative · entry 1 MACKAY MARTIN · CIK 0001414815 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,343 Underlying: Common Stock · 104 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.